口服Chk1抑制剂CCT244747增强膀胱癌与头颈癌细胞系放射敏感性
该研究在膀胱癌和头颈癌细胞系及移植瘤模型中,评估了首个口服生物利用的Chk1抑制剂CCT244747联合放疗的增敏作用。结果显示CCT244747在体外增敏细胞系,在体内导致肿瘤生长延迟并伴生存获益。其放射增敏机制与消除辐射诱导的G2期阻滞和提前进入有丝分裂有关。
要点
- CCT244747是首个口服生物利用的Chk1抑制剂,在膀胱癌和头颈癌细胞系中具有放射增敏作用。
- 体内移植瘤模型中,CCT244747联合放疗导致肿瘤生长延迟并伴生存获益。
- 放射增敏机制为消除辐射诱导的G2期阻滞并促使细胞提前进入有丝分裂。
核心结论
- CCT244747是一种强效且特异的Chk1抑制剂,可口服给药,能增敏肿瘤细胞系,是与放疗联合应用的新临床治疗选择。
研究设计与样本
- 研究使用一组膀胱癌和头颈癌细胞系,在体外和体内模型中监测CCT244747联合放疗的效果。
主要发现
- CCT244747在体外增敏癌细胞系对放疗的敏感性。
- 在癌症移植瘤模型中,CCT244747联合放疗导致肿瘤生长延迟,并伴有生存获益。
- 放射增敏由消除辐射诱导的G2期阻滞和提前进入有丝分裂所引发。
临床怎么用
- CCT244747可口服给药,作为Chk1抑制剂与放疗联合,可能成为膀胱癌和头颈癌的临床治疗新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, their clinical progress has been hampered by low bioavailability and off-target toxicities. MATERIALS AND METHODS: We characterized the radiosensitizing activity of CCT244747, the first orally bioavailable Chk1 inhibitor. We used a panel of bladder and head and neck cancer cell lines and monitored the effect of combining CCT244747 with radiation both in in vitro and in vivo models. RESULTS: CCT244747 sensitized cancer cell lines to radiation in vitro and resulted in a growth delay in cancer xenograft models associated with a survival benefit. Radiosensitization was elicited by abrogation of the radiation-induced G2 arrest and premature entry into mitosis. CONCLUSIONS: CCT244747 is a potent and specific Chk1 inhibitor that can be administered orally. It radiosensitizes tumour cell lines and represents a new therapy for clinical application in combination with radiotherapy.
引用
- Patel R, Barker HE, Kyula J, et al. An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. Radiother Oncol. 2017. PMID: 28131548. doi:10.1016/j.radonc.2016.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。